ABN AMRO Bank N.V. Invests $624,000 in AstraZeneca PLC $AZN

ABN AMRO Bank N.V. acquired a new position in AstraZeneca PLC (NASDAQ:AZN) in the 3rd quarter, Holdings Channel.com reports. The firm acquired 8,164 shares of the company’s stock, valued at approximately $624,000.

Other institutional investors also recently bought and sold shares of the company. Altrius Capital Management Inc lifted its position in AstraZeneca by 1.3% during the third quarter. Altrius Capital Management Inc now owns 119,560 shares of the company’s stock valued at $9,173,000 after purchasing an additional 1,538 shares in the last quarter. HighPoint Advisor Group LLC raised its stake in shares of AstraZeneca by 8.2% in the third quarter. HighPoint Advisor Group LLC now owns 29,029 shares of the company’s stock worth $2,227,000 after buying an additional 2,202 shares during the period. Bessemer Group Inc. lifted its position in shares of AstraZeneca by 4.8% during the 3rd quarter. Bessemer Group Inc. now owns 106,095 shares of the company’s stock valued at $8,140,000 after buying an additional 4,850 shares in the last quarter. Triglav Investments D.O.O. lifted its position in shares of AstraZeneca by 12.6% during the 3rd quarter. Triglav Investments D.O.O. now owns 100,199 shares of the company’s stock valued at $7,687,000 after buying an additional 11,217 shares in the last quarter. Finally, Howe & Rusling Inc. grew its stake in shares of AstraZeneca by 0.3% during the 3rd quarter. Howe & Rusling Inc. now owns 117,593 shares of the company’s stock valued at $9,022,000 after acquiring an additional 407 shares during the period. 20.35% of the stock is owned by institutional investors.

AstraZeneca Price Performance

AstraZeneca stock opened at $187.58 on Friday. The firm’s fifty day moving average is $99.82 and its 200 day moving average is $87.54. The company has a quick ratio of 0.69, a current ratio of 0.88 and a debt-to-equity ratio of 0.54. The company has a market cap of $290.92 billion, a price-to-earnings ratio of 62.32, a PEG ratio of 1.59 and a beta of 0.34. AstraZeneca PLC has a 52-week low of $61.24 and a 52-week high of $192.79.

AstraZeneca (NASDAQ:AZN) last released its quarterly earnings results on Thursday, November 6th. The company reported $1.19 EPS for the quarter, topping the consensus estimate of $1.14 by $0.05. AstraZeneca had a return on equity of 32.89% and a net margin of 16.17%.The company had revenue of $15.19 billion during the quarter, compared to analyst estimates of $14.75 billion. During the same quarter last year, the business posted $2.08 earnings per share. The firm’s revenue was up 12.0% on a year-over-year basis. Sell-side analysts forecast that AstraZeneca PLC will post 4.51 EPS for the current fiscal year.

Wall Street Analyst Weigh In

AZN has been the topic of several analyst reports. Wall Street Zen downgraded shares of AstraZeneca from a “strong-buy” rating to a “buy” rating in a report on Saturday, January 17th. Jefferies Financial Group initiated coverage on shares of AstraZeneca in a research note on Monday, October 27th. They set a “buy” rating on the stock. Citigroup started coverage on AstraZeneca in a research note on Tuesday, January 27th. They issued a “buy” rating for the company. Deutsche Bank Aktiengesellschaft reissued a “sell” rating on shares of AstraZeneca in a report on Friday, January 16th. Finally, Barclays reaffirmed an “overweight” rating on shares of AstraZeneca in a research note on Tuesday, January 6th. Ten equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $95.75.

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca’s operations span research and development, large-scale manufacturing, and commercial distribution, with a presence in developed and emerging markets worldwide.

The company focuses on several core therapy areas including oncology, cardiovascular, renal and metabolism (CVRM), respiratory and immunology, and rare diseases.